Ruxolitinib cream 1.5% Demonstrates Tolerability, Safety Over 52 Weeks in Children

Pediatric Atopic Dermatitis

Ruxolitinib cream 1.5% demonstrated consistently good tolerability and safety over 52 weeks in children 2 to 11 years old with extensive moderate-to-severe atopic dermatitis (AD) in a study presented this month at the Revolutionizing Atopic Dermatitis (RAD) Conference in Chicago, Illinois.

Eight-week safety and tolerability, efficacy, and limited systemic absorption in an open-label, single-arm, maximum-use trial had been previously described, but the first report of longer-term data from the same study came in “Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2–11 years: 52 week results from a maximum-use trial,” presented at RAD by Robert Bissonnette, MD, and colleagues.

The maximum-use trial included 29 patients with moderate-to-severe AD. Treatment- emergent adverse events through Week 52 occurred in 31.0% of patients. One patient (3.4%) had two treatment-related application site reactions (paresthesia and folliculitis); no adverse events resulted in treatment interruption/discontinuation; none were serious or suggested systemic JAK inhibition.

“Through the 4-week continuous-use twice-daily treatment period, the mean (SD) application quantity was 8.5 (6.29) g/day, which was associated with a mean steady-state ruxolitinib plasma concentration of 98.2 nM, well below half-maximal concentration of JAK–mediated myelosuppression in adults (281 nM),” the presenters noted. “From Week 8 to Week 52 (as-needed use), mean (SD) application quantity was 3.2 (2.79) g/day, consistent with lower, as-needed use in this long-term safety period. At Weeks 4 and 52 (assessed in n=26 and n=13 patients, respectively), 53.8%/53.8% achieved IGA–Treatment Success (IGA 0/1 with ≥2-grade improvement from baseline). Mean BSA decreased from 58.0% (range, 35.0%–92.0%) at baseline (n=29) to 11.4% at Week 4 and continued to decrease to 2.2% through Week 52 (n=26 and n=14, respectively). Patient-reported outcomes, such as the Patient-Oriented Eczema Measure, Children's Dermatology Life Quality Index, and Infants' Dermatitis Quality of Life Index, were collected through Week 52.”

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free